The merger is structured as a share-swap, with QCIL shareholders receiving 977 shares of Aster DM for every 1,000 QCIL shares. Post-merger, Blackstone will hold a 30.7% stake, while Aster’s promoters will own 24%, and the remainder will be held by public and other shareholders.
Delivered Good to Decent Numbers With Margins Improving (exits from low-margin businesses), 8% YoY rise in consolidated revenue and a 21% YoY increase in operating EBITDA.
They Said they will increase capacity to ~7,800 beds in FY26
Q4 FY26: They have posted a good set of numbers. Their ARPOB has increased to around 54,000. This has been a result of better case mix (higher value surgeries, cardiology, neurosciences..), exiting of low yield businesses and focus on premium specialities. The main indication has been that management is prioritizing quality over growth.